Lantern Pharma director granted new stock options

Lantern Pharma Inc. director Chandru Vijay reported receiving two new stock option grants.

Rhea-AI Filing Summary

Lantern Pharma Inc. director Chandru Vijay reported receiving two new stock option grants. On January 9, 2026, he was granted stock options to buy 25,000 shares of common stock at an exercise price of $3.49 per share under the company’s Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.

On the same date, he also received stock options to buy an additional 17,307 shares of common stock at an exercise price of $3.49 per share under the same plan. This second grant vests in equal monthly installments over 12 months beginning February 9, 2026. Both grants are reported as directly owned derivative securities.

Insider Trade Summary

Grant/Award: 42,307 shares

Grant/Award 2 txns

Insider Chandru Vijay

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	17,307	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 42,307 contracts (Direct)

Footnotes (2)

1. F1. The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.
2. F2. The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lantern Pharma (LTRN) report for Vijay Chandru?

Lantern Pharma reported that director Vijay Chandru received two grants of stock options on January 9, 2026, covering 25,000 and 17,307 shares of common stock.

How many stock options did the Lantern Pharma director receive and at what exercise price?

He received options to buy 25,000 shares and 17,307 shares of Lantern Pharma common stock, each with an exercise price of $3.49 per share.

When do Vijay Chandru’s Lantern Pharma stock options start vesting and over what periods?

Both option grants start vesting on February 9, 2026. The 25,000-share grant vests monthly over 24 months, and the 17,307-share grant vests monthly over 12 months.

Under which plan were the Lantern Pharma stock options to Vijay Chandru granted?

Both grants were issued under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.

Are Vijay Chandru’s Lantern Pharma stock options reported as directly or indirectly owned?

The Form 4 reports both stock option grants as directly owned derivative securities by Vijay Chandru.

What type of securities did Vijay Chandru receive from Lantern Pharma?

He received stock options (rights to buy) Lantern Pharma common stock, classified as derivative securities on the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/13/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chandru Vijay

(Last) (First) (Middle)

1920 MCKINNEY AVENUE, 7TH FLOOR

(Street)

DALLAS TX 75201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lantern Pharma Inc. [ LTRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.49	01/09/2026		A		25,000		(1)	01/08/2036	Common Stock	25,000	$0.00	25,000	D
Stock Option (Right to Buy)	$3.49	01/09/2026		A		17,307		(2)	01/08/2036	Common Stock	17,307	$0.00	17,307	D

Explanation of Responses:

1. The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.

2. The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.

	/s/ Vijay Chandru	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.